{
    "id": 23888,
    "fullName": "ERBB2 T798I",
    "impact": "missense",
    "proteinEffect": "no effect - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ERBB2 (HER2) T798I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). T798I does not result in activation of Erbb2 (Her2) downstream signaling or transformation of cultured cells, but is associated with resistance to Erbb2 (Her2) inhibitors (PMID: 25238247, PMID: PMID: 28274957, PMID: 18413839) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.",
            "references": [
                {
                    "id": 6146,
                    "pubMedId": 25238247,
                    "title": "Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25238247"
                },
                {
                    "id": 5983,
                    "pubMedId": 18413839,
                    "title": "EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413839"
                },
                {
                    "id": 9156,
                    "pubMedId": 28274957,
                    "title": "An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28274957"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "T798I",
    "createDate": "06/29/2016",
    "updateDate": "10/10/2018",
    "referenceTranscriptCoordinates": {
        "id": 170776,
        "transcript": "NM_004448",
        "gDna": "chr17:g.39724811C>T",
        "cDna": "c.2393C>T",
        "protein": "p.T798I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839).",
            "molecularProfile": {
                "id": 24613,
                "profileName": "ERBB2 T798I"
            },
            "therapy": {
                "id": 967,
                "therapyName": "XL647",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5983,
                    "pubMedId": 18413839,
                    "title": "EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18413839"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7333,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",
            "molecularProfile": {
                "id": 24613,
                "profileName": "ERBB2 T798I"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6146,
                    "pubMedId": 25238247,
                    "title": "Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25238247"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7330,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",
            "molecularProfile": {
                "id": 24613,
                "profileName": "ERBB2 T798I"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6146,
                    "pubMedId": 25238247,
                    "title": "Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25238247"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11219,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lobular breast carcinoma patient harboring ERBB2 L869R and ERBB3 E928G demonstrated an initial response to treatment with Nerlynx (neratinib), but subsequently developed resistance, which was associated with acquisition of ERBB2 T798I (PMID: 28274957).",
            "molecularProfile": {
                "id": 27928,
                "profileName": "ERBB2 T798I ERBB2 L869R ERBB3 E928G"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 50938,
                "name": "breast lobular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9156,
                    "pubMedId": 28274957,
                    "title": "An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28274957"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24613,
            "profileName": "ERBB2 T798I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27926,
            "profileName": "ERBB2 T798I ERBB2 L869R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27928,
            "profileName": "ERBB2 T798I ERBB2 L869R ERBB3 E928G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170777,
            "transcript": "NM_001289937",
            "gDna": "chr17:g.39724811C>T",
            "cDna": "c.2393C>T",
            "protein": "p.T798I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 170776,
            "transcript": "NM_004448",
            "gDna": "chr17:g.39724811C>T",
            "cDna": "c.2393C>T",
            "protein": "p.T798I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}